XML 51 R40.htm IDEA: XBRL DOCUMENT v3.7.0.1
(LOSS) EARNINGS PER SHARE (Tables)
 6 Months Ended
Jun. 30, 2017
Earnings Per Share [Abstract]  
Schedule of calculation of earnings per share
(Loss) earnings per share attributable to Valeant Pharmaceuticals International, Inc. for the three and six months ended June 30, 2017 and 2016 were calculated as follows:
 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
(in millions, except per share amounts)
2017
 
2016
 
2017
 
2016
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.
$
(38
)
 
$
(302
)
 
$
590

 
$
(676
)
 
 
 
 
 
 
 
 
Basic weighted-average number of common shares outstanding
350.1

 
345.0

 
350.0

 
344.9

Diluted effect of stock options, RSUs and other
—

 
—

 
0.9

 
—

Diluted weighted-average number of common shares outstanding
350.1

 
345.0

 
350.9

 
344.9

 
 
 
 
 
 
 
 
(Loss) earnings per share attributable to Valeant Pharmaceuticals International, Inc.:
 
 
 
 
 
 
 
Basic
$
(0.11
)
 
$
(0.88
)
 
$
1.69

 
$
(1.96
)
Diluted
$
(0.11
)
 
$
(0.88
)
 
$
1.68

 
$
(1.96
)
Schedule of antidilutive securities excluded from earnings per share
The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been as follows:
(in millions)
Three months ended
June 30, 2017
 
Three months ended
June 30, 2016
 
Six months ended
June 30, 2016
Basic weighted-average number of common shares outstanding
350.1

 
345.0

 
344.9

Diluted effect of stock options, RSUs and other
1.3

 
4.1

 
4.8

Diluted weighted-average number of common shares outstanding
351.4

 
349.1

 
349.7